The prognostic value of 19S ATPase proteasome subunits in acute myeloid leukemia and other forms of cancer

Introduction: The ubiquitin-proteasome system (UPS) is an intracellular organelle responsible for targeted protein degradation, which represents a standard therapeutic target for many different human malignancies. Bortezomib, a reversible inhibitor of chymotrypsin-like proteasome activity, was first approved by the FDA in 2003 to treat multiple myeloma and is now used to treat a number of different cancers, including relapsed mantle cell lymphoma, diffuse large B-cell lymphoma, colorectal cancer, and thyroid carcinoma. Despite the success, bortezomib and other proteasome inhibitors are subject to severe side effects, and ultimately, drug resistance. We recently reported an oncogenic role for non-ATPase members of the 19S proteasome in chronic myeloid leukemia (CML), acute myeloid leukemia (AML), and several different solid tumors. In the present study, we hypothesized that ATPase members of the 19S proteasome would also serve as biomarkers and putative therapeutic targets in AML and multiple other cancers.

Methods: We used data from The Cancer Genome Atlas (TCGA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC) available at UALCAN and/or GEPIA2 to assess the expression and prognostic value of proteasome 26S subunit, ATPases 1-6 (PSMC1-6) of the 19S proteasome in cancer. UALCAN was also used to associate PSMC1-6 mRNA expression with distinct clinicopathological features. Finally, cBioPortal was employed to assess genomic alterations of PSMC genes across different cancer types.

Results: The mRNA and protein expression of PSMC1-6 of the 19S proteasome were elevated in several cancers compared with normal controls, which often correlated with worse overall survival. In contrast, AML patients demonstrated reduced expression of these proteasome subunits compared with normal mononuclear cells. However, AML patients with high expression of PSMC2-5 had worse outcomes.

Discussion: Altogether, our data suggest that components of the 19S proteasome could serve as prognostic biomarkers and novel therapeutic targets in AML and several other human malignancies.

1. Introduction

The ubiquitin-proteasome system (UPS) is the key intracellular machinery for protein degradation, regulating the localization and stability of thousands of proteins within a cell (1). The UPS encompasses a series of essential components, including ubiquitin, ubiquitin-activating enzymes (E1s), ubiquitin-conjugating enzymes (E2s), ubiquitin ligases (E3s), deubiquitinating enzymes (DUBs), and the 26S proteasome (2–4). Due to the major role of the UPS in maintaining protein homeostasis, it is a central player in regulating essential cellular functions, including cell differentiation, cell cycle progression, apoptosis, DNA repair, and drug resistance (5–8). The widespread influence of the UPS on cell biology has important implications for human health, as abnormal UPS function is associated with numerous human conditions, including neurodegenerative diseases, autoimmune diseases, and cancer (9, 10). For this reason, a number of small molecule inhibitors targeting the UPS were developed for therapeutic intervention, but unfortunately, drug resistance and toxicity remain significant challenges (11, 12), especially in hematopoietic cells (13–15). Novel therapeutic approaches will be required to effectively target the UPS with less toxicity.

The 26S proteasome is comprised of two main subcomplexes, the 20S core complex and the 19S regulatory complex, which work together to recognize ubiquitylated peptides and promote UPS-dependent protein degradation (Figure 1) (22–25). The 20S core complex contains the protein degradative machinery, whereas the 19S regulatory complex functions by recognizing, binding, unfolding, and translocating ubiquitylated peptides into the 20S core complex for degradation (22, 23, 26). Traditional proteasome inhibitors (e.g., bortezomib, carfilzomib, ixazomib) function by binding to and inhibiting the 20S core complex. Bortezomib (Velcade^®), a reversible inhibitor of chymotrypsin-like proteasome activity, acts by binding to and inhibiting the 20S beta 5 subunit of the proteasome (β5, PSMB5) (27), leading to the accumulation of ubiquitylated proteins and cell death (28). However, proteasome inhibitors like bortezomib are prone to resistance mechanisms, due to mutations in the molecular target of bortezomib, PSMB5, highlighting the need for alternative therapeutic strategies (29–31).

FIGURE 1

Figure 1. Structure of the 26S proteasome. Subunits of the 20S core particle and 19S regulatory particles are shown. The 20S core complex consists of α1/PSMA1-α7/PSMA7 and β1/PSMB1-β7/PSMB7. The 19S regulatory particles consist of two structures: a base (Rpt1/PSMC1-Rpt6/PSMC6, Rpn1/PSMD2, Rpn2/PSMD1, Rpn10/PSMD10, and Rpn13/ADRM1) and a lid (Rpn3/PSMD3, Rpn4/PSMD10-Rpn9/PSMD13, Rpn11/PSMD14, Rpn12/PSMD8, and Rpn15/SEM1). Rpn4/PSMD9 acts as a chaperone during assembly of the base of the 19S regulatory complex (16). Redrawn from refs (17–21).

One strategy to overcome proteasome inhibitor resistance is to target the 19S regulatory complex instead of the 20S core complex. Importantly, the 19S complex contains numerous components subdivided into ATP-dependent and ATP-independent subunits (Figure 1) (32). The ATP-dependent subunits include the proteasome 26S subunit, ATPases 1–6 (PSMC1-6, Supplementary Table S1), which make up the base of the 19S complex, whereas the ATP-independent subunits include proteasome 26S subunit, non-ATPases 1–16 (PSMD1-16) (25), which make up the 19S lid (33). The lid is important for interactions with ubiquitin, whereas the base is required for unfolding the protein to allow it to enter the 20S core (22). The ATPase subunits play critical roles in substrate engagement, unfolding, translocation, and opening the gate of the core complex (34–37). Several groups have demonstrated the potential for targeting the 19S adhesion-regulating molecule 1 (ADRM1/hRPN13) protein in bortezomib resistance (38–44), leading to the development of the putative ADRM1/hRPN13 inhibitor, RA190 (45–48). Intriguingly, data from our lab and others demonstrated that certain members of the 19S lid might serve as better molecular targets for proteasome inhibition (24, 25, 38, 49–51). Indeed, our research has shown that knockdown of 26S proteasome non-ATPases 1 (PSMD1/hRPN2) and 3 (PSMD3/hRPN3), two members of the 19S regulatory complex (17), impaired survival and induced apoptosis of myeloid leukemia cells but not normal cord blood CD34⁺ hematopoietic stem and progenitor cells (25, 49), implying they may be good molecular targets for proteasome inhibition in human diseases. However, while the PSMD subunits of the 19S proteasome are non-ATPases that do not contain catalytically active target sites, the PSMC subunits are ATPases that could be targeted more efficiently with small molecule inhibitors. Therefore, we hypothesized that ATPase members of the 19S proteasome would serve as biomarkers and putative therapeutic targets in acute myeloid leukemia and several different solid tumors. Using data from The Cancer Genome Atlas (TCGA) and the Clinical Proteomic Tumor Analysis Consortium (CPTAC), expression of the ATPase PSMC subunits of the 19S proteasome was elevated in several cancers compared with normal controls, which often correlated with worse overall survival. Altogether, our data suggest that components of the 19S proteasome could serve as prognostic biomarkers and novel therapeutic targets in multiple human malignancies.

2. Materials and methods

2.1. Analysis of PSMC differential mRNA and protein expression across TCGA cancers compared with normal tissue

UALCAN (The University of ALabama at Birmingham CANcer data analysis portal)¹ is a comprehensive, interactive platform for in-depth analyses of TCGA and CPTAC data (52). This portal helped us identify potential candidates based on mRNA and protein expression data across different tumor stages and cancer types compared with normal tissue. The cancers we investigated included acute myeloid leukemia (LAML), adrenocortical carcinoma (ACC), bladder urothelial carcinoma (BLCA), breast invasive carcinoma (BRCA), cervical squamous cell carcinoma and endocervical adenocarcinoma (CESC), cholangiocarcinoma (CHOL), colorectal adenocarcinoma (COAD), diffuse large B-cell lymphoma (DLBCL), esophageal carcinoma (ESCA), glioblastoma multiforme (GBM), head and neck squamous cell carcinoma (HNSC), kidney chromophobe (KICH), kidney renal clear cell carcinoma (KIRC), kidney renal papillary cell carcinoma (KIRP), liver hepatocellular carcinoma (LIHC), low-grade glioma (LGG), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), mesothelioma (MESO), ovarian serous cystadenocarcinoma (OV), pancreatic adenocarcinoma (PAAD), pheochromocytoma and paraganglioma (PCPG), prostate adenocarcinoma (PRAD), rectum adenocarcinoma (READ), sarcoma (SARC), skin cutaneous melanoma (SKCM), stomach adenocarcinoma (STAD), testicular germ cell tumors (TGCT), thymoma (THYM), thyroid carcinoma (THCA), uterine carcinosarcoma (UCS), uterine corpus endometrial carcinoma (UCEC), and uveal melanoma (UVM). The comparison of mRNA expression for PSMC subunits between tumor and normal tissues was further studied using GEPIA2 (Gene Expression Profiling Interactive Analysis 2)², an integrated web-based platform for analyzing gene expression data from TCGA and the Genotype-Tissue Expression (GTEx) projects (53). Data are presented using box plots.

2.2. Correlation of PSMC mRNA expression with prognostic significance across different cancer types

Along with the gene expression analyses described above, we also used UALCAN to correlate gene expression levels for PMSC1-6 with overall survival across TCGA cancers. Data are presented using Kaplan–Meier curves.

2.3. Correlation of PSMC mRNA expression with distinct clinicopathological features in different cancer types

UALCAN also provided the mRNA expression of PSMC subunits across cancer types comparing different cancer stages. We chose to focus on the expression of PSMC1-6 across tumor stages for patients with BRCA, LIHC, KICH, and LUAD. Additionally, we assessed PSMC1-6 expression in AML patients with mutated versus unaltered FMS-like tyrosine kinase 3 (FLT3) using data from UALCAN and the BEAT AML trial (ClinicalTrials.gov Identifier: NCT03013998) available at Vizome³ (54, 55).

2.4. Genomic alterations of PSMC genes across different cancer types

cBioPortal⁴ is another online database for cancer genomics used to explore and visualize genomic data across cancer studies (56). Therefore, we analyzed the frequency and different types of genetic mutations in PSMC subunit genes across different human cancers.

2.5. Statistical analyzes

Differences in PSMC gene and protein expression levels were calculated in UALCAN using the Student’s t-test, whereas GEPIA2 data were analyzed using the one-way ANOVA test. Data are presented using box plots. Correlations of gene expression with overall survival are presented using Kaplan–Meier curves (UALCAN uses a 25% cutoff for analysis of survival data). A value of p of <0.05 was considered statistically significant for all analyzes.

3. Results

3.1. mRNA encoding proteasome subunits were often downregulated in AML versus normal progenitors, but patients with higher expression levels had a worse prognosis

Work from our lab and others had documented increased expression of several 19S proteasome subunits in multiple cancer types compared with normal tissue (24, 49, 51, 57–60). Our previous work in AML studying the non-ATPase subunits of the 19S proteasome revealed that PSMD2, PSMD3, PSMD7, and PSMD9 mRNA expression levels were reduced in AML versus normal progenitors, but that high levels of expression correlated with worse overall survival in AML patients (25). In fact, the downregulation of proteasome subunits is a universal feature of AML compared with normal mononuclear cells. For the 20S proteasome, PSMA4, PSMA5, PSMA7, and all seven PSMB subunits are downregulated in AML versus normal controls (Supplementary Figure S1). However, similar to our observations for PSMD3 (25), patients with higher expression levels tended to have worse outcomes (Supplementary Figures S2, S3).

In the present study, we hypothesized that ATPase members of the 19S proteasome would show a similar expression pattern, and that is indeed what we observed. PSMC2, PSMC3, and PSMC4 mRNA expression were significantly reduced in AML versus normal progenitor cells, whereas no change was observed for PSMC1, PSMC5, or PSMC6 (Figures 2A–F, left). These data were confirmed using the GEPIA2 database (Supplementary Figure S4). Despite this observation, TCGA data available at UALCAN showed that AML patients with higher than average levels of PSMC2, PSMC3, PSMC4, and PSMC5 mRNA expression had a significant reduction in overall survival compared with patients expressing low to medium levels of those genes when all AML subtypes were considered (Figures 2A–F, right).

FIGURE 2

Figure 2. High levels of PSMC subunit expression correlated with worse overall survival in acute myeloid leukemia (AML). (A–F). Box plots (left) and Kaplan–Meier curves (right) show the expression of PSMC1 (A), PSMC2 (B), PSMC3 (C), PSMC4 (D), PSMC5 (E), and PSMC6 (F) mRNA in AML versus normal specimens and their correlation with overall survival. *p < 0.001.

We previously demonstrated that high levels of PSMD3 mRNA expression led to a sharp reduction in overall survival for AML patients harboring FLT3 mutations (25). We next asked whether the expression of ATPase subunits of the 19S proteasome was altered in AML patients with mutated versus wild-type FLT3 and whether they correlated with overall survival. TCGA data available at UALCAN demonstrated that the genes encoding PSMC1 (p = 0.009), PSMC2 (p = 0.027), and PSMC5 (p = 0.032) were significantly upregulated in AML patients with mutated versus wild-type FLT3 (Figures 3A–F). PSMC5 upregulation in FLT3+ AML was confirmed using data from the BEAT AML trial available at Vizome.org (Supplementary Figure S5) (54, 55). Consistent with a potential role for these proteins in drug resistance of AML, patients with high levels of PSMC2, PSMC4, and PSMC5 mRNA expression had significantly worse overall survival in FLT3-mutated and FLT3-unaltered AML patients (Figures 4A–F). More specifically, high levels of PSMC4 expression affected both FLT3-mutated (green curve) and FLT3-unaltered patients (pink curve, Figure 4D), whereas patients with high levels of PSMC2 or PSMC5 primarily affected AML patients with unaltered FLT3 (pink curves, Figures 4B,E). Altogether, these data implicate PSMC2, PSMC4, and PSMC5, all ATPase subunits of the 19S proteasome, as putative oncogenes in AML, depending on FLT3 status.

FIGURE 3

Figure 3. Correlation of PSMC subunit expression with FLT3 mutation status in AML. (A–F) We used TCGA data available at UALCAN to associate the expression of PSMC subunits with FLT3 mutation status in AML. The box plots demonstrate PSMC1 (A), PSMC2 (B), PSMC3 (C), PSMC4 (D), PSMC5 (E), and PSMC6 (F) mRNA expression comparing AML patients with mutated versus wild-type FLT3.

FIGURE 4

Figure 4. High levels of PSMC2, PSMC4, and PSMC5 mRNA expression correlated with worse outcomes in AML patients with mutated and/or wild-type FLT3. (A–F). Kaplan–Meier curves show the effects of PSMC1 (A), PSMC2 (B), PSMC3 (C), PSMC4 (D), PSMC5 (E), and PSMC6 (F) mRNA expression on overall survival comparing AML patients with mutated versus wild-type (unaltered) FLT3.

3.2. Expression of PSMC subunits of the 19S proteasome were elevated at the mRNA and protein levels in multiple solid tumors compared with normal tissue

Prior studies have demonstrated that the expression of several different PSMC proteasome subunits is increased in lung cancer, breast cancer, and multiple myeloma (58–61). Therefore, we hypothesized that the relevance of PSMC 19S proteasome subunits might stretch beyond AML to other types of cancers. At the mRNA level, TCGA data available at UALCAN demonstrated that the expression of PSMC1 (15/24 tumors, 62.5%), PSMC2 (17/24 tumors, 70.8%), PSMC3 (13/24 tumors, 54.2%), PSMC4 (12/24 tumors, 50%), PSMC5 (13/24 tumors, 54.2%), and PSMC6 (10/24 tumors, 41.7%) mRNA were significantly elevated in several different tumor types compared with normal tissue (Figure 5A; Supplementary Figures S6, S7). For instance, BLCA, BRCA, CHOL, COAD, ESCA, HNSC, LICH, LUAD, LUSC, and STAD cancers demonstrated increased expression of all six PSMC subunits (Figure 5A; Supplementary Figures S6, S7). On the other hand, patients with glioblastoma (GBM) showed increased expression of PSMC2, but decreased expression of PSMC5 and PSMC6. Patients with kidney chromophobe (KICH) were the marked exception, demonstrating reduced expression of PSMC1, PSMC2, PSMC3, PSMC4, and PSMC5 in tumor versus normal tissues (Figure 5A; Supplementary Figures S6, S7).

FIGURE 5

Figure 5. 19S PSMC subunit expression at the mRNA and protein level in multiple types of solid tumors. (A,B) The heat maps show the significant p values comparing PSMC mRNA (A) and protein (B) levels in all TCGA cancers versus normal specimens, excluding LAML. p values indicating significant PSMC upregulation are indicated in black; p values indicating significant PSMC downregulation are indicated in white. BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colorectal adenocarcinoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; PAAD, pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; RCC, renal cell carcinoma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; THCA, thyroid carcinoma; THYM, thymoma; STAD, stomach adenocarcinoma; UCEC, uterine corpus endometrial carcinoma.

Similar to the mRNA data, CPTAC data available at UALCAN revealed that the expression of PSMC1 (6/10 tumors, 60%), PSMC2 (8/10 tumors, 80%), PSMC3 (6/10 tumors, 60%), PSMC4 (6/10 tumors, 60%), PSMC5 (6/10 tumors, 60%), and PSMC6 (5/10 tumors, 50%) proteins were significantly elevated in several different tumor types compared with normal tissue (Figure 5B; Supplementary Figures S8, S9). Importantly, patients with colon cancer, ovarian cancer, clear cell renal cell carcinoma (RCC), UCEC, and lung cancer demonstrated increased expression of all six PSMC protein subunits. On the other hand, patients with breast cancer, who presented increased expression of all six PSMC mRNAs, showed a significant reduction of PSMC3, PSMC5, and PSMC6 protein levels. Patients with PAAD or liver cancer also demonstrated reduced expression of PSMC protein subunits (Figure 5B; Supplementary Figures S8, S9). Altogether, these data further implicate the ATPase subunits of the 19S proteasome as oncogenes in AML and other types of cancers.

3.3. High expression of PSMC subunits correlated with worse outcomes in a number of different human malignancies

Since high expression of ATPase members of the 19S proteasome correlated with worse outcomes in AML (Figures 2, 4), we hypothesized that similar results would be observed in other types of cancers. All six ATPase subunits of the 19S proteasome correlated with worse overall survival in multiple human malignancies, but the expression of PSMC4 appeared to have the greatest effect (Figure 6). High levels of PSMC4 mRNA expression yielded worse outcomes in eight different malignancies, including patients with ACC (p = 0.01), LGG (p < 0.0001), LICH (p = 0.00025), LUAD (p = 0.0055), MESO (p = 0.052), SKCM (p = 0.012), THYM (p = 0.038), and UVM (p = 0.0003; Figures 6A–H). While AML patients with high PSMC1 expression had a worse overall survival (Figures 2, 4), PSMC1 mRNA expression had little effect on outcomes in solid tumors, except for patients with LUAD and LUSC. Interestingly, high levels of PSMC1 mRNA expression correlated with worse outcomes in LUAD (p = 0.05), but better outcomes in LUSC (p = 0.028; Figure 7A). Similarly, patients with high levels of PSMC2 expression demonstrated reduced overall survival for patients with KICH (p = 0.00013) and LIHC (p = 0.022; Figure 7B). High levels of PSMC3 expression correlated with worse outcomes for patients with KICH (p = 0.0025), LIHC (p = 0.03), and LUAD (p = 0.021; Figure 7C). High levels of PSMC5 correlated with better outcomes in patients with LGG (p = 0.0073), but worse overall survival in patients with KICH (p = 0.01) and LIHC (p = 0.015; Figure 7D). Finally, high levels of PSMC6 significantly reduced overall survival in patients with ESCA (p = 0.018), LIHC (p = 0.0026), and LUAD (p = 0.0017; Figure 7E). Altogether, ATPase members of the 19S proteasome were frequently upregulated in multiple types of cancers, which correlated with worse outcomes.

FIGURE 6

Figure 6. PSMC4 expression correlated with worse overall survival in multiple human malignancies. (A–H) TCGA data available at UALCAN demonstrate that higher levels of PSMC4 mRNA expression correlated with worse outcomes for adrenocortical carcinoma ACC (A), brain lower grade glioma LGG, (B) liver hepatocellular carcinoma LIHC, (C) lung adenocarcinoma LUAD, (D) mesothelioma MESO, (E) skin cutaneous melanoma SKCM, (F) thymoma THYM, (G) and uveal melanoma UVM (H).

FIGURE 7

Figure 7. Expression of PSMC1, 2, 3, 5, and 6 also correlated with changes in overall survival in different solid tumors. (A–E) Kaplan–Meier curves show the effects of PSMC1 (A), PSMC2 (B), PSMC3 (C), PSMC5 (D), and PSMC6 (E) mRNA expression on overall survival in the specified solid tumors. ESCA, esophageal carcinoma; KICH, kidney chromophobe; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma.

3.4. Correlation of PSMC subunit expression with distinct clinicopathological features in patients with BRCA, KICH, LIHC, and LUAD

According to data from UALCAN, the mRNA expression of PSMC subunits differs significantly among different tumor stages in certain types of cancers. In BRCA, for example, expression of PSMC2, PSMC3, and PSMC5 were elevated in stages 1–4 compared with normal tissues, with the highest levels observed at stage 4 (Figures 8A–F). Interestingly, PSMC1 expression increased in BRCA patients who progressed from stage 1 to stages 2–3 of the disease (Figure 8A). In KICH, on the other hand, the expression levels of all PSMC subunits were significantly reduced in stages 1, 2, and 3 compared with normal tissues (p < 0.05; Supplementary Figures S10A–F). However, with the exception of PSMC1, a notable feature in KICH is a distinct upregulation of PSMC2-6 subunit expression during stage 4 of the disease (Supplementary Figures S10B–F). In LIHC, expression of all six PSMC subunits was elevated in stages 1–4 compared with normal tissues. PSMC4, PSMC5, and PSMC6 expression increased in patients progressing from stage 1 to stages 2–3 of the disease (Figures 9A–F). In contrast, while all six PSMC subunits were elevated in stages 1–4 compared with normal tissue in patients with LUAD, expression was not changed when comparing different stages of the disease (Supplementary Figure S11). These differences in the pattern of ATPase expression suggest a potential method for staging BRCA, KICH, LIHC, and possibly other tumors to provide prognostic information.

FIGURE 8

Figure 8. PSMC subunit expression correlated with tumor staging in breast invasive carcinoma (BRCA). (A–F) The box plots represent PSMC1 (A), PSMC2 (B), PSMC3 (C), PSMC4 (D), PSMC5 (E), and PSMC6 (F) mRNA expression in stages 1–4 of BRCA compared with normal samples from The Cancer Genome Atlas (TCGA).

FIGURE 9

Figure 9. PSMC subunit expression correlated with tumor staging in liver hepatocellular carcinoma (LIHC). (A–F) The box plots represent PSMC1 (A), PSMC2 (B), PSMC3 (C), PSMC4 (D), PSMC5 (E), and PSMC6 (F) mRNA expression in stages 1–4 of LIHC compared with normal samples from The Cancer Genome Atlas (TCGA). *p < 0.05; **p < 0.01; ***p < 0.001.

3.5. Genomic alterations of PSMC subunits in cancer

To better understand the causes of these PSMC gene expressions changes in cancer, we used cBioPortal to identify the genomic mutations identified through TCGA. AML showed deep deletions for PSMC2 and mutations in PSMC6, with no other abnormalities in the other subunits (Figures 10A–F). PSMC1 DNA is prone to mutations, amplifications, and deep deletions, with mutations documented as the most common change (Figure 10A). On the other hand, PSMC2, PSMC4, and PSMC5 are primarily prone to amplifications, whereas PSMC3 and PSMC6 are more likely to have a combination of mutations and amplifications (Figures 10B–F). Notably, KICH has deep deletions for PSMC1, amplifications for PSMC2, and mutations for PSMC6, with no other abnormalities observed in the other subunits (Figures 10A–F). Altogether, mutations, deep deletions, and amplifications could explain the differences in PSMC gene expression in certain types of cancers.

FIGURE 10

Figure 10. Genomic alterations in the genes encoding PSMC1-6 in multiple human cancers. Using data from cBioPortal, the bar graphs show genomic alterations associated with PSMC1 (A), PSMC2 (B), PSMC3 (C), PSMC4 (D), PSMC5 (E), and PSMC6 (F) in all of the cancers available in TCGA. ACC, adrenocortical carcinoma; BLCA, bladder urothelial carcinoma; BRCA, breast invasive carcinoma; CESC, cervical squamous cell carcinoma and endocervical adenocarcinoma; CHOL, cholangiocarcinoma; COAD, colorectal adenocarcinoma; DLBCL, diffuse large B-cell lymphoma; ESCA, esophageal carcinoma; GBM, glioblastoma multiforme; HNSC, head and neck squamous cell carcinoma; KICH, kidney chromophobe; KIRC, kidney renal clear cell carcinoma; KIRP, kidney renal papillary cell carcinoma; LAML, acute myeloid leukemia; LGG, brain lower grade glioma; LIHC, liver hepatocellular carcinoma; LUAD, lung adenocarcinoma; LUSC, lung squamous cell carcinoma; MESO, mesothelioma; OV, ovarian serous cystadenocarcinoma; PAAD, pancreatic adenocarcinoma; PRAD, prostate adenocarcinoma; PCPG, pheochromocytoma and paraganglioma; READ, rectum adenocarcinoma; SARC, sarcoma; SKCM, skin cutaneous melanoma; STAD, stomach adenocarcinoma; TGCT, testicular germ cell tumor; THCA, thyroid carcinoma; THYM, thymoma; UCEC, uterine corpus endometrial carcinoma; UCS, uterine carcinosarcoma; UVM, uveal melanoma.

4. Discussion

The ubiquitin-proteasome system (UPS) is a multi-protein complex that plays a critical role in regulating protein homeostasis, apoptosis, and a number of other cellular processes. Cancers can have abnormally increased proteasome activity due to the high metabolic demands for cancer growth that require rapid protein turnover. Therefore, the UPS has become a spotlight in research as a therapeutic target for various cancers. Standard proteasome inhibitors bind to and inhibit the 20S core complex of the UPS (27). However, proteasome inhibitors like bortezomib are prone to resistance mechanisms, highlighting the need for alternative therapeutic strategies (29–31). One strategy to overcome proteasome inhibitor resistance is to target the 19S regulatory complex instead of the 20S core complex. Indeed, knockdown of the 19S PSMD3 subunit significantly impaired the stability of human epidermal growth factor 2 (HER2) in breast cancer, which induced apoptosis and inhibited the growth, proliferation, and colony formation of tumor cells. Furthermore, a high level of PSMD3 mRNA expression was associated with shorter overall survival in breast cancer, especially in HER2+ patients (51). Similarly, our data demonstrated that PSMD3 expression is highly upregulated in chronic myeloid leukemia (CML) patients who have progressed from the chronic to the rapidly fatal blast phase of the disease (49). In marked contrast, however, patients with AML demonstrated reduced expression of PSMD3 mRNA compared with normal specimens (25). Despite this observation, AML patients with higher than average levels of PSMD3 expression had worse outcomes, especially for patients with FLT3 mutations (25). Importantly, PSMD3 knockdown impaired survival and induced apoptosis of CML and AML cells, but not normal cord blood progenitors (25, 49), indicating it may be a good potential target for cancer therapy.

The PSMD subunits of the 19S proteasome are non-ATPases that harbor no catalytically active target sites, which may make them poor cancer drug targets. On the other hand, the PSMC subunits of the 19S proteasome are ATPases that harbor catalytically active target sites. Indeed, proton pump inhibitors, also known as H+/K+ ATPase modulators, have attracted much attention for their clinical implication in gastric acid-related diseases (62, 63), whereas vacuolar ATPase inhibitors are being studied as a potential treatment for therapy-resistant cancers (64). Therefore, we hypothesized that ATPase members of the 19S proteasome would serve as biomarkers of disease progression and possible therapeutic targets in AML and multiple solid tumors, and this was indeed what we observed. Similar to our observations for PSMD3 (25), mRNA encoding PSMC2, PSMC3, and PSMC4 were surprisingly downregulated in AML versus normal mononuclear cells (Figure 2). We speculate that low proteasome subunit expression may explain the suboptimal response of AML patients to proteasome inhibition in certain clinical trials (65). Despite the reduced subunit expression, AML patients with high levels of PSMC2, PSMC3, PSMC4, and PSMC5 expression had a worse overall survival compared with patients demonstrating low-to-medium levels of expression (Figure 2). Interestingly, PSMC1, PSMC2, and PSMC5 mRNA expression were significantly higher in AML patients with mutated versus wild-type FLT3 (Figure 3), which correlated with worse outcomes in the case of PSMC2 and PSMC5 (Figure 4). In the case of solid tumors, all six PSMC subunits were upregulated at the mRNA and/or protein level in multiple different cancers, which in some cases correlated with worse outcomes (Figures 5–7). DNA mutations, deep deletions, or amplifications may explain the differences in PSMC gene expression observed in certain types of cancers.

As mentioned previously, high expression of all six ATPase subunits of the 19S proteasome correlated with worse overall survival in multiple human malignancies. However, the expression of PSMC4 appeared to have the greatest effect, correlating with reduced overall survival in 8/24 TCGA tumors (Figure 6). The first evidence for an oncogenic role of PSMC4 was in prostate cancer. In that study, expression of the genes encoding PSMC4, PSMB5, and the E3 ubiquitin ligase NEDD4L, were significantly upregulated in prostate cancer cells compared with the corresponding adjacent normal prostate tissue (66). PSMC4 was also shown to facilitate interactions between the proteasome and the endoplasmic reticulum, allowing for cellular ubiquitination of specific mitochondrial proteins (67). Interestingly, this association was shown to favor the resistance of breast cancer cells to anthracycline treatments (68). Additionally, the proteasome is dynamically phosphorylated during the cell cycle at threonine 25 of the 19S PSMC4 subunit, which contributes to cell proliferation and tumorigenesis (37). Through a kinome-wide screen, they identified dual-specificity tyrosine-regulated kinase 2 (DYRK2) as the primary kinase that phosphorylates PSMC4, leading to enhanced peptide translocation and degradation (37). Genome editing or small-molecule mediated inhibition of DYRK2 significantly bypassed bortezomib resistance in both multiple myeloma and breast cancer cells (69). PSMC4 is also considered a biomarker in endometrial cancer (70–72), breast cancer (60), hepatocellular carcinoma (73), oral squamous cell carcinoma (74), and laryngeal carcinoma (75). Combined with our data in the present study, PSMC4 may be a novel biomarker and therapeutic target for drug-resistant cancer patients demonstrating high levels of PSMC4 expression.

Consistent with our findings, higher proteasome activity has been detected in colon cancer tissue compared with the surrounding normal tissue (76). Furthermore, PSMC2-6 were shown to be more highly expressed at the mRNA and protein level in breast cancer compared with normal breast tissue, which again correlated with worse outcomes (60). Proteasome inhibitors like bortezomib, carfilzomib, or ixazomib have been very effective in the treatment of multiple myeloma, but resistance to therapy is still a major obstacle (13–15, 27, 30). These drugs target the PSMB5 subunit of the 20S proteasome, and mutations in PSMB5 can confer drug resistance in in vitro models (31). However, an analysis of 1,500 multiple myeloma patients revealed that these mutations were rare in the clinic (31). A recent meta-analysis study investigated the potential role of PSMC subunits in multiple myeloma and the correlation of mRNA expression with proteasome inhibitor resistance. This analysis included approximately 2000 newly diagnosed and advanced multiple myeloma patients, demonstrating 36 single nucleotide variants in the ATP/ADP binding pockets, which affected the conformation of individual subunits and the structure of the proteasome as a whole. For instance, an acquired mutation of PSMC2 at Y429S after bortezomib therapy correlated with relapse, thereby confirming an association of PSMC2 with proteasome inhibitor resistance (61). Another study identified 19S proteasome subunits as key determinants of resistance to proteasome inhibitors. This study performed a bortezomib screening on the KBM7 human myeloid leukemia cell line, revealing that PSMC2-6 served as key players in proteasome inhibitor resistance, and that downregulation of PSMC5 increased proteasome inhibitor resistance (77). Combined with our data, the PSMC subunits of the 19S proteasome could be novel prognostic biomarkers and putative therapeutic targets in AML and multiple types of solid tumors. These novel cancer drug targets are worthy of future investigation in the fields of cancer therapy and drug resistance.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary material, further inquiries can be directed to the corresponding author.

Author contributions

BT: data curation, investigation, methodology, writing-original draft, writing-review and editing, visualization, and formal analysis. JA: data curation, investigation, methodology, writing-original draft, writing-review and editing, visualization, and formal analysis. MG and IO: data curation, investigation, visualization, supervision, writing-original draft, and writing-review and editing. JS, MK, VV, EM, DT, AR, CJ, and DE: writing-review and editing. AE: conceptualization, methodology, formal analysis, data curation, supervision, validation, writing-original draft, and writing-review and editing. All authors contributed to the article and approved the submitted version.

Funding

This work was funded by the Elsa U. Pardee Foundation (AE), the Scholarly Activity and Research Program (SARP) at Paul L. Foster School of Medicine, and the Department of Molecular and Translational Medicine at Texas Tech University Health Sciences Center at El Paso.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fmed.2023.1209425/full#supplementary-material

Footnotes

1. ^http://ualcan.path.uab.edu/, accessed on January 12, 2023.

2. ^http://gepia2.cancer-pku.cn, accessed on January 12, 2023.

3. ^http://vizome.org, accessed on March 22, 2023.

4. ^https://www.cbioportal.org, accessed on January 13, 2023.

References

1. Collins, GA, and Goldberg, AL. The logic of the 26S proteasome. Cells. (2017) 169:792–806. doi: 10.1016/j.cell.2017.04.023

PubMed Abstract | CrossRef Full Text | Google Scholar

2. Okamoto, Y, Ozaki, T, Miyazaki, K, Aoyama, M, Miyazaki, M, and Nakagawara, A. UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme. Cancer Res. (2003) 63:4167–73.

PubMed Abstract | Google Scholar

3. Pickart, CM, and Eddins, MJ. Ubiquitin: structures, functions, mechanisms. Biochim Biophys Acta. (2004) 1695:55–72. doi: 10.1016/j.bbamcr.2004.09.019

CrossRef Full Text | Google Scholar

4. Davis, C, Spaller, BL, and Matouschek, A. Mechanisms of substrate recognition by the 26S proteasome. Curr Opin Struct Biol. (2021) 67:161–9. doi: 10.1016/j.sbi.2020.10.010

PubMed Abstract | CrossRef Full Text | Google Scholar

5. Liu, CH, Goldberg, AL, and Qiu, XB. New insights into the role of the ubiquitin-proteasome pathway in the regulation of apoptosis. Chang Gung Med J. (2007) 30:469–79.

PubMed Abstract | Google Scholar

6. Daulny, A, and Tansey, WP. Damage control: DNA repair, transcription, and the ubiquitin-proteasome system. DNA Repair. (2009) 8:444–8. doi: 10.1016/j.dnarep.2009.01.017

PubMed Abstract | CrossRef Full Text | Google Scholar

7. Olguín, HC. The gentle side of the UPS: ubiquitin-proteasome system and the regulation of the myogenic program. Front Cell Dev Biol. (2021) 9:821839. doi: 10.3389/fcell.2021.821839

CrossRef Full Text | Google Scholar

8. Frescas, D, and Pagano, M. Deregulated proteolysis by the F-box proteins SKP2 and beta-TrCP: tipping the scales of cancer. Nat Rev Cancer. (2008) 8:438–49. doi: 10.1038/nrc2396

CrossRef Full Text | Google Scholar

9. Yadav, D, Lee, JY, Puranik, N, Chauhan, PS, Chavda, V, Jin, JO, et al. Modulating the ubiquitin-proteasome system: a therapeutic strategy for autoimmune diseases. Cells. (2022) 11:1093. doi: 10.3390/cells11071093

PubMed Abstract | CrossRef Full Text | Google Scholar

10. Cao, Y, Zhu, H, He, R, Kong, L, Shao, J, Zhuang, R, et al. Proteasome, a promising therapeutic target for multiple diseases beyond Cancer. Drug Des Devel Ther. (2020) 14:4327–42. doi: 10.2147/DDDT.S265793

PubMed Abstract | CrossRef Full Text | Google Scholar

11. Piperdi, B, Ling, YH, Liebes, L, Muggia, F, and Perez-Soler, R. Bortezomib: understanding the mechanism of action. Mol Cancer Ther. (2011) 10:2029–30. doi: 10.1158/1535-7163.MCT-11-0745

CrossRef Full Text | Google Scholar

12. Zhang, X, Linder, S, and Bazzaro, M. Drug development targeting the ubiquitin-proteasome system (UPS) for the treatment of human cancers. Cancers. (2020) 12:902. doi: 10.3390/cancers12040902

PubMed Abstract | CrossRef Full Text | Google Scholar

13. Imtiaz, H, Khan, M, Ehsan, H, Wahab, A, Rafae, A, Khan, AY, et al. Efficacy and toxicity profile of carfilzomib-based regimens for treatment of newly diagnosed multiple myeloma: a systematic review. Onco Targets Ther. (2021) 14:4941–60. doi: 10.2147/OTT.S317570

PubMed Abstract | CrossRef Full Text | Google Scholar

14. Yan, W, Wu, Z, Zhang, Y, Hong, D, Dong, X, Liu, L, et al. The molecular and cellular insight into the toxicology of bortezomib-induced peripheral neuropathy. Biomed Pharmacother. (2021) 142:112068. doi: 10.1016/j.biopha.2021.112068

PubMed Abstract | CrossRef Full Text | Google Scholar

15. Groen, K, van de Donk, N, Stege, C, Zweegman, S, and Nijhof, IS. Carfilzomib for relapsed and refractory multiple myeloma. Cancer Manag Res. (2019) 11:2663–75. doi: 10.2147/CMAR.S150653

PubMed Abstract | CrossRef Full Text | Google Scholar

16. Sahu, I, Sangith, N, Ramteke, M, Gadre, R, and Venkatraman, P. A novel role for the proteasomal chaperone PSMD9 and hnRNPA1 in enhancing IκBα degradation and NF-κB activation - functional relevance of predicted PDZ domain-motif interaction. FEBS J. (2014) 281:2688–709. doi: 10.1111/febs.12814

PubMed Abstract | CrossRef Full Text | Google Scholar

17. D'Arcy, P, Wang, X, and Linder, S. Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacol Ther. (2015) 147:32–54. doi: 10.1016/j.pharmthera.2014.11.002

CrossRef Full Text | Google Scholar

18. Lasker, K, Forster, F, Bohn, S, Walzthoeni, T, Villa, E, Unverdorben, P, et al. Molecular architecture of the 26S proteasome holocomplex determined by an integrative approach. Proc Natl Acad Sci U S A. (2012) 109:1380–7. doi: 10.1073/pnas.1120559109

PubMed Abstract | CrossRef Full Text | Google Scholar

19. Lander, GC, Estrin, E, Matyskiela, ME, Bashore, C, Nogales, E, and Martin, A. Complete subunit architecture of the proteasome regulatory particle. Nature. (2012) 482:186–91. doi: 10.1038/nature10774

PubMed Abstract | CrossRef Full Text | Google Scholar

20. Stone, HR, and Morris, JR. DNA damage emergency: cellular garbage disposal to the rescue? Oncogene. (2014) 33:805–13. doi: 10.1038/onc.2013.60

PubMed Abstract | CrossRef Full Text | Google Scholar

21. Marshall, RS, and Vierstra, RD. Dynamic regulation of the 26S proteasome: from synthesis to degradation. Front Mol Biosci. (2019) 6:40. doi: 10.3389/fmolb.2019.00040

PubMed Abstract | CrossRef Full Text | Google Scholar

22. Liu, CW, and Jacobson, AD. Functions of the 19S complex in proteasomal degradation. Trends Biochem Sci. (2013) 38:103–10. doi: 10.1016/j.tibs.2012.11.009

PubMed Abstract | CrossRef Full Text | Google Scholar

23. Tanaka, K. The proteasome: overview of structure and functions. Proc Jpn Acad Ser B Phys Biol Sci. (2009) 85:12–36. doi: 10.2183/pjab.85.12

PubMed Abstract | CrossRef Full Text | Google Scholar

24. Rubio, AJ, Bencomo-Alvarez, AE, Young, JE, Velazquez, VV, Lara, JJ, Gonzalez, MA, et al. 26S proteasome non-ATPase regulatory subunits 1 (PSMD1) and 3 (PSM3) as putative targets for cancer prognosis and therapy. Cells. (2021) 10:2390. doi: 10.3390/cells10092390

PubMed Abstract | CrossRef Full Text | Google Scholar

25. Lara, JJ, Bencomo-Alvarez, AE, Gonzalez, MA, Olivas, IM, Young, JE, Lopez, JL, et al. 19S proteasome subunits as oncogenes and prognostic biomarkers in FLT3-mutated acute myeloid leukemia (AML). Int J Mol Sci. (2022) 23:14586. doi: 10.3390/ijms232314586

PubMed Abstract | CrossRef Full Text | Google Scholar

26. Cetin, G, Klafack, S, Studencka-Turski, M, Kruger, E, and Ebstein, F. The ubiquitin-proteasome system in immune cells. Biomol Ther. (2021) 11:60. doi: 10.3390/biom11010060

PubMed Abstract | CrossRef Full Text | Google Scholar

27. Dou, QP, and Zonder, JA. Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin-proteasome system. Curr Cancer Drug Targets. (2014) 14:517–36. doi: 10.2174/1568009614666140804154511

PubMed Abstract | CrossRef Full Text | Google Scholar

28. Cloos, J, Roeten, MS, Franke, NE, van Meerloo, J, Zweegman, S, Kaspers, GJ, et al. (Immuno)proteasomes as therapeutic target in acute leukemia. Cancer Metastasis Rev. (2017) 36:599–615. doi: 10.1007/s10555-017-9699-4

PubMed Abstract | CrossRef Full Text | Google Scholar

29. Oerlemans, R, Franke, NE, Assaraf, YG, Cloos, J, van Zantwijk, I, Berkers, CR, et al. Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein. Blood. (2008) 112:2489–99. doi: 10.1182/blood-2007-08-104950

PubMed Abstract | CrossRef Full Text | Google Scholar

30. Allmeroth, K, Horn, M, Kroef, V, Miethe, S, Müller, RU, and Denzel, MS. Bortezomib resistance mutations in PSMB5 determine response to second-generation proteasome inhibitors in multiple myeloma. Leukemia. (2021) 35:887–92. doi: 10.1038/s41375-020-0989-4

PubMed Abstract | CrossRef Full Text | Google Scholar

31. Shi, CX, Zhu, YX, Bruins, LA, Bonolo de Campos, C, Stewart, W, Braggio, E, et al. Proteasome subunits differentially control myeloma cell viability and proteasome inhibitor sensitivity. Mol Cancer Res. (2020) 18:1453–64. doi: 10.1158/1541-7786.MCR-19-1026

PubMed Abstract | CrossRef Full Text | Google Scholar

32. Dubiel, W, Ferrell, K, and Rechsteiner, M. Subunits of the regulatory complex of the 26S protease. Mol Biol Rep. (1995) 21:27–34. doi: 10.1007/BF00990967

CrossRef Full Text | Google Scholar

33. Kish-Trier, E, and Hill, CP. Structural biology of the proteasome. Annu Rev Biophys. (2013) 42:29–49. doi: 10.1146/annurev-biophys-083012-130417

PubMed Abstract | CrossRef Full Text | Google Scholar

34. Finley, D. Recognition and processing of ubiquitin-protein conjugates by the proteasome. Annu Rev Biochem. (2009) 78:477–513. doi: 10.1146/annurev.biochem.78.081507.101607

PubMed Abstract | CrossRef Full Text | Google Scholar

35. Bhattacharyya, S, Yu, H, Mim, C, and Matouschek, A. Regulated protein turnover: snapshots of the proteasome in action. Nat Rev Mol Cell Biol. (2014) 15:122–33. doi: 10.1038/nrm3741

PubMed Abstract | CrossRef Full Text | Google Scholar

36. Ehlinger, A, and Walters, KJ. Structural insights into proteasome activation by the 19S regulatory particle. Biochemistry. (2013) 52:3618–28. doi: 10.1021/bi400417a

PubMed Abstract | CrossRef Full Text | Google Scholar

37. Guo, X, Wang, X, Wang, Z, Banerjee, S, Yang, J, Huang, L, et al. Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis. Nat Cell Biol. (2016) 18:202–12. doi: 10.1038/ncb3289

PubMed Abstract | CrossRef Full Text | Google Scholar

38. Anchoori, RK, Karanam, B, Peng, S, Wang, JW, Jiang, R, Tanno, T, et al. A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell. (2013) 24:791–805. doi: 10.1016/j.ccr.2013.11.001

PubMed Abstract | CrossRef Full Text | Google Scholar

39. Song, Y, Ray, A, Li, S, Das, DS, Tai, YT, Carrasco, RD, et al. Targeting proteasome ubiquitin receptor Rpn13 in multiple myeloma. Leukemia. (2016) 30:1877–86. doi: 10.1038/leu.2016.97

PubMed Abstract | CrossRef Full Text | Google Scholar

40. Lu, X, Nowicka, U, Sridharan, V, Liu, F, Randles, L, Hymel, D, et al. Structure of the Rpn13-Rpn2 complex provides insights for Rpn13 and Uch37 as anticancer targets. Nat Commun. (2017) 8:15540. doi: 10.1038/ncomms15540

PubMed Abstract | CrossRef Full Text | Google Scholar

41. VanderLinden, RT, Hemmis, CW, Yao, T, Robinson, H, and Hill, CP. Structure and energetics of pairwise interactions between proteasome subunits RPN2, RPN13, and ubiquitin clarify a substrate recruitment mechanism. J Biol Chem. (2017) 292:9493–504. doi: 10.1074/jbc.M117.785287

PubMed Abstract | CrossRef Full Text | Google Scholar

42. Hemmis, CW, Heard, SC, and Hill, CP. Phosphorylation of Tyr-950 in the proteasome scaffolding protein RPN2 modulates its interaction with the ubiquitin receptor RPN13. J Biol Chem. (2019) 294:9659–65. doi: 10.1074/jbc.AC119.008881

PubMed Abstract | CrossRef Full Text | Google Scholar

43. Song, Y, Park, PMC, Wu, L, Ray, A, Picaud, S, Li, D, et al. Development and preclinical validation of a novel covalent ubiquitin receptor Rpn13 degrader in multiple myeloma. Leukemia. (2019) 33:2685–94. doi: 10.1038/s41375-019-0467-z

PubMed Abstract | CrossRef Full Text | Google Scholar

44. Song, Y, Du, T, Ray, A, Chauhan, K, Samur, M, Munshi, N, et al. Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13. Blood Cancer J. (2021) 11:13. doi: 10.1038/s41408-020-00398-9

PubMed Abstract | CrossRef Full Text | Google Scholar

45. Dickson, P, Abegg, D, Vinogradova, E, Takaya, J, An, H, Simanski, S, et al. Physical and functional analysis of the putative Rpn13 inhibitor RA190. Cell. Chem Biol. (2020) 27:1371–1382 e6.

Google Scholar

46. Osei-Amponsa, V, Sridharan, V, Tandon, M, Evans, CN, Klarmann, K, Cheng, KT, et al. Impact of losing hRpn13 Pru or UCHL5 on proteasome clearance of Ubiquitinated proteins and RA190 cytotoxicity. Mol Cell Biol. (2020) 40:e00122. doi: 10.1128/MCB.00122-20

CrossRef Full Text | Google Scholar

47. Soong, RS, Anchoori, RK, Roden, RBS, Cho, RL, Chen, YC, Tseng, SC, et al. Bis-benzylidine Piperidone RA190 treatment of hepatocellular carcinoma via binding RPN13 and inhibiting NF-kappaB signaling. BMC Cancer. (2020) 20:386. doi: 10.1186/s12885-020-06896-0

PubMed Abstract | CrossRef Full Text | Google Scholar

48. Yu, GY, Wang, X, Zheng, SS, Gao, XM, Jia, QA, Zhu, WW, et al. RA190, a proteasome subunit ADRM1 inhibitor, suppresses intrahepatic cholangiocarcinoma by inducing NF-KB-mediated cell apoptosis. Cell Physiol Biochem. (2018) 47:1152–66. doi: 10.1159/000490210

PubMed Abstract | CrossRef Full Text | Google Scholar

49. Bencomo-Alvarez, AE, Rubio, AJ, Olivas, IM, Gonzalez, MA, Ellwood, R, Fiol, CR, et al. Proteasome 26S subunit, non-ATPases 1 (PSMD1) and 3 (PSMD3), play an oncogenic role in chronic myeloid leukemia by stabilizing nuclear factor-kappa B. Oncogene. (2021) 40:2697–710. doi: 10.1038/s41388-021-01732-6

PubMed Abstract | CrossRef Full Text | Google Scholar

50. Boland, K, Flanagan, L, McCawley, N, Pabari, R, Kay, EW, McNamara, DA, et al. Targeting the 19S proteasomal subunit, Rpt4, for the treatment of colon cancer. Eur J Pharmacol. (2016) 780:53–64. doi: 10.1016/j.ejphar.2016.03.031

PubMed Abstract | CrossRef Full Text | Google Scholar

51. Fararjeh, AS, Chen, LC, Ho, YS, Cheng, TC, Liu, YR, Chang, HL, et al. Proteasome 26S subunit, non-ATPase 3 (PSMD3) regulates breast Cancer by stabilizing HER2 from degradation. Cancers. (2019) 11:527. doi: 10.3390/cancers11040527

PubMed Abstract | CrossRef Full Text | Google Scholar

52. Chandrashekar, DS, Bashel, B, Balasubramanya, SAH, Creighton, CJ, Ponce-Rodriguez, I, Chakravarthi, B, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses. Neoplasia. (2017) 19:649–58. doi: 10.1016/j.neo.2017.05.002

CrossRef Full Text | Google Scholar

53. Tang, Z, Kang, B, Li, C, Chen, T, and Zhang, Z. GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis. Nucleic Acids Res. (2019) 47:W556–w560. doi: 10.1093/nar/gkz430

PubMed Abstract | CrossRef Full Text | Google Scholar

54. Tyner, JW, Tognon, CE, Bottomly, D, Wilmot, B, Kurtz, SE, Savage, SL, et al. Functional genomic landscape of acute myeloid leukaemia. Nature. (2018) 562:526–31. doi: 10.1038/s41586-018-0623-z

PubMed Abstract | CrossRef Full Text | Google Scholar

55. Bottomly, D, Long, N, Schultz, AR, Kurtz, SE, Tognon, CE, Johnson, K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. (2022) 40:850–864.e9. doi: 10.1016/j.ccell.2022.07.002

PubMed Abstract | CrossRef Full Text | Google Scholar

56. Cerami, E, Gao, J, Dogrusoz, U, Gross, BE, Sumer, SO, Aksoy, BA, et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. (2012) 2:401–4. doi: 10.1158/2159-8290.CD-12-0095

PubMed Abstract | CrossRef Full Text | Google Scholar

57. Okumura, T, Ikeda, K, Ujihira, T, Okamoto, K, Horie-Inoue, K, Takeda, S, et al. Proteasome 26S subunit PSMD1 regulates breast cancer cell growth through p53 protein degradation. J Biochem. (2018) 163:19–29. doi: 10.1093/jb/mvx053

PubMed Abstract | CrossRef Full Text | Google Scholar

58. Jia, H, Tang, WJ, Sun, L, Wan, C, Zhou, Y, and Shen, WZ. Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma. Front Genet. (2022) 13:1017866.

Google Scholar

59. Ullah, MA, Islam, NN, Moin, AT, Park, SH, and Kim, B. Evaluating the prognostic and therapeutic potentials of the proteasome 26S subunit, ATPase (PSMC) family of genes in lung adenocarcinoma: a database mining approach. Front Genet. (2022) 13:935286. doi: 10.3389/fgene.2022.935286

PubMed Abstract | CrossRef Full Text | Google Scholar

60. Kao, TJ, Wu, CC, Phan, NN, Liu, YH, Ta, HDK, Anuraga, G, et al. Prognoses and genomic analyses of proteasome 26S subunit, ATPase (PSMC) family genes in clinical breast cancer. Aging (Albany NY). (2021) 13:17970. doi: 10.18632/aging.203345

PubMed Abstract | CrossRef Full Text | Google Scholar

61. Haertle, L, Buenache, N, Cuesta Hernández, HN, Simicek, M, Snaurova, R, Rapado, I, et al. Genetic alterations in members of the proteasome 26S subunit, AAA-ATPase (PSMC) gene family in the light of proteasome inhibitor resistance in multiple myeloma. Cancers. (2023) 15:532. doi: 10.3390/cancers15020532

PubMed Abstract | CrossRef Full Text | Google Scholar

62. Yatime, L, Buch-Pedersen, MJ, Musgaard, M, Morth, JP, Lund Winther, AM, Pedersen, BP, et al. P-type ATPases as drug targets: tools for medicine and science. Biochim Biophys Acta. (2009) 1787:207–20. doi: 10.1016/j.bbabio.2008.12.019

PubMed Abstract | CrossRef Full Text | Google Scholar

63. Scarpignato, C, Pelosini, I, and Di Mario, F. Acid suppression therapy: where do we go from here? Dig Dis. (2006) 24:11–46. doi: 10.1159/000091298

PubMed Abstract | CrossRef Full Text | Google Scholar

64. Whitton, B, Okamoto, H, Packham, G, and Crabb, SJ. Vacuolar ATPase as a potential therapeutic target and mediator of treatment resistance in cancer. Cancer Med. (2018) 7:3800–11. doi: 10.1002/cam4.1594

PubMed Abstract | CrossRef Full Text | Google Scholar

65. Aplenc, R, Meshinchi, S, Sung, L, Alonzo, T, Choi, J, Fisher, B, et al. Bortezomib with standard chemotherapy for children with acute myeloid leukemia does not improve treatment outcomes: a report from the Children's oncology group. Haematologica. (2020) 105:1879–86. doi: 10.3324/haematol.2019.220962

PubMed Abstract | CrossRef Full Text | Google Scholar

66. Hellwinkel, OJ, Asong, LE, Rogmann, JP, Sültmann, H, Wagner, C, Schlomm, T, et al. Transcription alterations of members of the ubiquitin-proteasome network in prostate carcinoma. Prostate Cancer Prostatic Dis. (2011) 14:38–45. doi: 10.1038/pcan.2010.48

PubMed Abstract | CrossRef Full Text | Google Scholar

67. Amoroso, MR, Matassa, DS, Laudiero, G, Egorova, AV, Polishchuk, RS, Maddalena, F, et al. TRAP1 and the proteasome regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins. Cell Death Differ. (2012) 19:592–604. doi: 10.1038/cdd.2011.128

PubMed Abstract | CrossRef Full Text | Google Scholar

68. Sisinni, L, Maddalena, F, Lettini, G, Condelli, V, Matassa, DS, Esposito, F, et al. TRAP1 role in endoplasmic reticulum stress protection favors resistance to anthracyclins in breast carcinoma cells. Int J Oncol. (2014) 44:573–82. doi: 10.3892/ijo.2013.2199

PubMed Abstract | CrossRef Full Text | Google Scholar

69. Banerjee, S, Wei, T, Wang, J, Lee, JJ, Gutierrez, HL, Chapman, O, et al. Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression. Proc Natl Acad Sci U S A. (2019) 116:24881–91. doi: 10.1073/pnas.1912033116

PubMed Abstract | CrossRef Full Text | Google Scholar

70. Zhou, H, Zhang, C, Li, H, Chen, L, and Cheng, X. A novel risk score system of immune genes associated with prognosis in endometrial cancer. Cancer Cell Int. (2020) 20:240. doi: 10.1186/s12935-020-01317-5

PubMed Abstract | CrossRef Full Text | Google Scholar

71. Ding, H, Fan, GL, Yi, YX, Zhang, W, Xiong, XX, and Mahgoub, OK. Prognostic implications of immune-related Genes' (IRGs) signature models in cervical Cancer and endometrial Cancer. Front Genet. (2020) 11:725. doi: 10.3389/fgene020.00725

PubMed Abstract | CrossRef Full Text | Google Scholar

72. Zhou, C, Li, C, Yan, F, and Zheng, Y. Identification of an immune gene signature for predicting the prognosis of patients with uterine corpus endometrial carcinoma. Cancer Cell Int. (2020) 20:541. doi: 10.1186/s12935-020-01560-w

PubMed Abstract | CrossRef Full Text | Google Scholar

73. Hassani, SF, Sayaf, M, Danandeh, SS, Nourollahzadeh, Z, Shahmohammadi, M, Akbari, S, et al. Novel insight into the association between obesity and hepatocellular carcinoma occurrence and recurrence: high-throughput microarray data set analysis of differentially expressed genes. JCO Clin Cancer Inform. (2021) 5:1169–80. doi: 10.1200/CCI.21.00094

PubMed Abstract | CrossRef Full Text | Google Scholar

74. Fan, Y, Zhang, J, Shi, J, Chen, L, Long, J, Zhang, S, et al. Genetic cross-talk between Oral squamous cell carcinoma and type 2 diabetes: the potential role of immunity. Dis Markers. (2022) 2022:6389906.

Google Scholar

75. Liu, B, Hu, Y, Wan, L, Wang, L, Cheng, L, Sun, H, et al. Proteomics analysis of cancer tissues identifies IGF2R as a potential therapeutic target in laryngeal carcinoma. Front Endocrinol (Lausanne). (2022) 13:1031210. doi: 10.3389/fendo.2022.1031210

PubMed Abstract | CrossRef Full Text | Google Scholar

76. Arlt, A, Bauer, I, Schafmayer, C, Tepel, J, Müerköster, SS, Brosch, M, et al. Increased proteasome subunit protein expression and proteasome activity in colon cancer relate to an enhanced activation of nuclear factor E2-related factor 2 (Nrf2). Oncogene. (2009) 28:3983–96. doi: 10.1038/onc.2009.264

PubMed Abstract | CrossRef Full Text | Google Scholar

77. Tsvetkov, P, Mendillo, ML, Zhao, J, Carette, JE, Merrill, PH, Cikes, D, et al. Compromising the 19S proteasome complex protects cells from reduced flux through the proteasome. Elife. (2015) 4:e08467. doi: 10.7554/eLife.08467

PubMed Abstract | CrossRef Full Text | Google Scholar